Type and frequency of BCR-ABL kinase domain mutations at the time of relapse
| TK domain mutation . | No. of patients . | Proportion of patients with a KD mutation, % . | Frequency by type, % . |
|---|---|---|---|
| All mutations | 21 | 80 | n.a. |
| P-loop | |||
| G250E | 5 | 24 | — |
| Q252H | 1 | 5 | — |
| Y253H* | 2 | 10 | 62 |
| E255K/V* | 4 | 19 | — |
| Others D276G | 1 | 5 | — |
| Contact site | |||
| F311I | 1 | 5 | — |
| T315I* | 4 | 19 | 28.5 |
| F317L | 1 | 5 | — |
| Activation site L384M* | 2 | 10 | 9.5 |
| Dual mutations | — | — | — |
| E255K/T315I | 1 | 4.7 | 9.5 |
| Y253H/L384M | 1 | 4.7 | — |
| Unmutated | 5 | n.a. | 21 |
| TK domain mutation . | No. of patients . | Proportion of patients with a KD mutation, % . | Frequency by type, % . |
|---|---|---|---|
| All mutations | 21 | 80 | n.a. |
| P-loop | |||
| G250E | 5 | 24 | — |
| Q252H | 1 | 5 | — |
| Y253H* | 2 | 10 | 62 |
| E255K/V* | 4 | 19 | — |
| Others D276G | 1 | 5 | — |
| Contact site | |||
| F311I | 1 | 5 | — |
| T315I* | 4 | 19 | 28.5 |
| F317L | 1 | 5 | — |
| Activation site L384M* | 2 | 10 | 9.5 |
| Dual mutations | — | — | — |
| E255K/T315I | 1 | 4.7 | 9.5 |
| Y253H/L384M | 1 | 4.7 | — |
| Unmutated | 5 | n.a. | 21 |
Leukemic-cell samples obtained at relapse were evaluated for the presence or absence (WT) of a BCR-ABL KD mutation by both D-HPLC and direct sequencing as described in “Patients and methods.” Only 2 patients harbored 2 mutations.
n.a. indicates not applicable; —, not available.
Including patient with dual mutation.